EMOTIV, a bioinformatics company advancing understanding of the human brain using electroencephalography (EEG), and X-trodes, a company bringing patch-style multi-modality electrodes to monitor the body’s electrophysiological signals, are collaborating on a solution for simultaneous at-home brain and physiological measurement.

The collaboration pairs X-trodes’ wearable sensing technology with EmotivPRO, EMOTIV’s EEG data platform for neuroscience research. X-trodes’ sensors are designed for a number of use cases where larger EEG devices are not ideal, such as sleep studies and kinesiology research. EMOTIV customers can now use X-trodes’ proprietary dry-printed electrodes to stream user-generated data through the EmotivPRO mobile app for processing and analysis on EMOTIV’s cloud-based platform. Meanwhile, X-trodes users can contribute to and benefit from EMOTIV’s brain data repository.

“Our community will immediately benefit from the ability to study how the brain works in a range of new circumstances and environments,” says Tan Le, founder and CEO of EMOTIV, in a release. “Adding new sensors to our platform that can accurately measure brain signals in natural settings creates exciting new opportunities for clinical research. The freedom to continuously measure and analyze real-world data without the limitations of the lab is a game-changer.”

X-trodes’ solution comprises dry-printed multi-electrode patches for EEG, EMG, and ECG signal measurement, and an accompanying data acquisition unit. The wireless electrode patches conform to the skin without the need for gels or solutions.

“We are proud to partner with EMOTIV, which has led the revolution for making brain research accessible to everyone,” says Ziv Peremen, PhD, CEO of X-trodes, in a release. “Combining our wearable technology with EMOTIV’s expertise and market reach will facilitate the introduction of a truly user-friendly, end-to-end solution for brain and physiological signal measurement.”

X-trodes have submitted a US Food and Drug Administration pre-submission and are moving forward to the full submission, expecting to get clearance during 2023.

X-trodes advisory board members include several experts in sleep medicine, neurology, cardiology, and pulmonology:

X-trodes technology is based on intellectual property developed over the last decade at Yael Hanein‘s nano-technology laboratory at Tel Aviv University. X-trodes collaborates with leading global healthcare providers, biotech and pharmaceutical companies, and research institutions.